Vestronidase alfa - Ultragenyx Pharmaceutical

Drug Profile

Vestronidase alfa - Ultragenyx Pharmaceutical

Alternative Names: Mepsevii; Recombinant beta-glucuronidase - Ultragenyx; Recombinant human beta glucuronidase; rhGUS; UX-003; Vestronidase alfa - vjbk

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Saint Louis University
  • Developer Ultragenyx Pharmaceutical
  • Class Glucuronidases
  • Mechanism of Action Glucuronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis VII
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mucopolysaccharidosis VII

Most Recent Events

  • 18 Dec 2017 Ultragenyx Pharmaceutical enters into an agreement to sell its Rare Paediatric Disease Priority Review Voucher to Novartis
  • 15 Dec 2017 Launched for Mucopolysaccharidosis VII (In adolescents, In children, In adults) in USA (IV)
  • 15 Nov 2017 Registered for Mucopolysaccharidosis VII (In adolescents, In children, In adults) in USA (IV) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top